SB
NBIX icon

Suntrust Banks’s Neurocrine Biosciences NBIX Stock Holding History

Suntrust Banks’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$3.1M Buy
34,447
+3,361
+11% +$314K 0.02% 465
2019
Q2 		$2.63M Buy
31,086
+4,619
+17% +$379K 0.01% 512
2019
Q1 		$2.33M Buy
26,467
+2,156
+9% +$180K 0.01% 519
2018
Q4 		$1.74M Buy
+24,311
New +$2.33M 0.01% 561
2014
Q2 		– Sell
-68,757
Closed -$1.11M – 1589
2014
Q1 		$1.11M Buy
+68,757
New +$1.18M ﹤0.01% 912

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Suntrust Banks's NBIX Position: Q3 2019 in Review

Suntrust Banks increased its Neurocrine Biosciences (NBIX) stake by 11% in Q3 2019, buying an estimated $314K and bringing the position to 34,447 shares worth $3.1M. The position accounts for 0.02% of the portfolio, ranked #465.

Suntrust Banks first reported a position in NBIX in Q1 2014 and has held it in 5 quarters since. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Suntrust Banks held 34,447 shares of Neurocrine Biosciences worth $3.1M as of Q3 2019.
  • Suntrust Banks bought 3,361 Neurocrine Biosciences shares in Q3 2019, an estimated $314K.
  • Neurocrine Biosciences made up 0.02% of Suntrust Banks's portfolio in Q3 2019, its #465 holding.
  • Suntrust Banks first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 5 quarters since.
  • 332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Suntrust Banks's 13F filing for Q3 2019, filed 12 Nov 2019.